Quantbot Technologies LP Sells 7,219 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Quantbot Technologies LP trimmed its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 35.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 13,024 shares of the company’s stock after selling 7,219 shares during the quarter. Quantbot Technologies LP’s holdings in Zevra Therapeutics were worth $109,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ZVRA. MetLife Investment Management LLC boosted its position in Zevra Therapeutics by 8.1% during the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after buying an additional 1,717 shares during the period. IFG Advisors LLC raised its stake in shares of Zevra Therapeutics by 10.0% during the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock valued at $242,000 after acquiring an additional 2,650 shares during the last quarter. Mystic Asset Management Inc. grew its stake in shares of Zevra Therapeutics by 1.9% in the fourth quarter. Mystic Asset Management Inc. now owns 313,347 shares of the company’s stock worth $2,613,000 after purchasing an additional 5,900 shares during the last quarter. SG Americas Securities LLC increased its holdings in Zevra Therapeutics by 54.6% in the fourth quarter. SG Americas Securities LLC now owns 23,500 shares of the company’s stock valued at $196,000 after purchasing an additional 8,302 shares during the period. Finally, Rhumbline Advisers raised its position in Zevra Therapeutics by 18.4% during the 4th quarter. Rhumbline Advisers now owns 68,053 shares of the company’s stock worth $568,000 after purchasing an additional 10,573 shares during the last quarter. 35.03% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode acquired 10,000 shares of Zevra Therapeutics stock in a transaction dated Wednesday, March 19th. The stock was purchased at an average cost of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares of the company’s stock, valued at $318,400. This represents a 33.33 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now directly owns 51,361 shares of the company’s stock, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,773 shares of company stock valued at $674,176. Company insiders own 2.40% of the company’s stock.

Zevra Therapeutics Stock Down 4.6 %

Shares of NASDAQ ZVRA opened at $7.49 on Tuesday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm has a market cap of $405.33 million, a PE ratio of -3.80 and a beta of 1.98. The company’s fifty day simple moving average is $7.89 and its 200 day simple moving average is $8.21. Zevra Therapeutics, Inc. has a 12-month low of $4.20 and a 12-month high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last released its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The company had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. As a group, sell-side analysts forecast that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on ZVRA shares. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group increased their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. JMP Securities set a $18.00 price target on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Guggenheim upped their price objective on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, March 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $22.29.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.